Figure 2.

Adropin has minimal beneficial effects on whole‐body insulin sensitivity in obese mice. (A) Body weights were matched between vehicle‐ and adropin (Adr)‐treated high‐fat diet (HFD) mice groups. (B) There was no significant difference in plasma insulin levels under basal or hyperinsulinemic‐euglycemic clamp conditions. (C, D, E) Treatment with adropin led to a small, but nonsignificant improvement in whole‐body insulin sensitivity as shown by an increased glucose infusion rate required to maintain and match euglycemia between the groups over the course of the clamp. N = 6–8.